STAT
OCTOBER 29, 2024
Sen. Elizabeth Warren (D-Mass.) is urging the Federal Trade Commission to scrutinize recent deals from McKesson and Cardinal Health to buy oncology practices, saying those transactions pose “clear, anticompetitive risks.” McKesson, Cardinal Health, and Cencora are the three dominant wholesalers that distribute drugs and medical products.
The Pharmacist
OCTOBER 29, 2024
Pharmacies must contact all patients dispensed a specific batch of the beta blocker labetalol that may contain the wrong medication, the Medicines and Healthcare Products Regulatory Agency (MHRA) has instructed. If batch traceability is not possible, all patients dispensed this product in the last six months must be contacted. In a class two medicines recall […] The post Pharmacies must contact labetalol patients following manufacturing mix-up appeared first on The Pharmacist.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 29, 2024
The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription drugs for millions of people with Medicare. The law laid out aggressive timelines for implementing the Medicare Drug Price Negotiation Program. As the director of Medicare, my team and I worked thoughtfully and diligently to stand up the program — on time and successfully.
The Pharmacist
OCTOBER 29, 2024
Informal referrals to community pharmacies deprive pharmacies of more than £115 million each year, Community Pharmacy England (CPE) has estimated. This is the amount that would have been paid if existing referral routes had been used appropriately by GPs and NHS 111, rather than patients being signposted informally to their local community pharmacy.
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
STAT
OCTOBER 29, 2024
Twenty years ago, a respected colleague asked me to perform a “poop transplant” on a local schoolteacher with multiply recurrent C. difficile infection. I was incredulous and skeptical, but my colleague (a friend but a forceful one) persisted until I ultimately acquiesced. Soon I was in a hazmat suit blenderizing stool and performing my first (subsequently named) fecal microbiota transplant, or FMT.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
STAT
OCTOBER 29, 2024
As Chinese biopharma companies rise on the international stage, they are increasingly finding VC partners — in the United States. U.S. companies have long signed licensing deals with Chinese drugmakers. But increasingly American venture capitalists are building U.S.-based companies from scratch to test and ultimately seek to commercialize innovative drugs developed in China.
The Pharmacist
OCTOBER 29, 2024
The barriers and opportunities involved in working collaboratively across different healthcare professions – including how pharmacists can work across the multidisciplinary team – have been explored during a House of Commons event. The event was hosted by Watford MP Matt Turmaine, sponsored by Dr Bharat Shah of Sigma Pharmaceuticals, and chaired by Professor Mahendra Patel, […] The post 'More we could do' to collaborate across professions, House of Commons event hears appeared fi
STAT
OCTOBER 29, 2024
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Hello and happy Tuesday, D.C. Diagnosis readers! We are one week from Election Day; I probably don’t need to remind you.
Drug Patent Watch
OCTOBER 29, 2024
In the rapidly evolving landscape of biotechnology and pharmaceutical development, contract development and manufacturing organizations (CDMOs) have become essential partners for companies seeking to bring innovative medicines to market. However, navigating the complexities of these partnerships can be daunting, especially for smaller biotech companies.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT
OCTOBER 29, 2024
WASHINGTON — Election season will bring a reckoning for members who took controversial positions on health care issues over the past year, and an opportunity for new members to make a mark in the next Congress. Some long-serving members such as Sens. Tammy Baldwin (D-Wis.) and Jon Tester (D-Mont.) and Republican Rep. David Schweikert of Arizona risk losing their seats as the political ground has shifted under them.
pharmaphorum
OCTOBER 29, 2024
The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership – which has seen a $150 million upfront payment from Novartis alongside a pledge for up to $2.1 billion in milestones – gives the Swiss pharma group rights to Monte Rosa's VAV1-directed molecular glue degrader programme.
STAT
OCTOBER 29, 2024
A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show. But it’s unclear whether the new dosing schedule, if approved by regulators, will convince doctors that the treatment is safer for patients. At 24 weeks of a Phase 3b trial, 24% of those taking the standard regimen experienced a side effect called ARIA-E, a kind of brain swelling.
PharmaVoice
OCTOBER 29, 2024
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
STAT
OCTOBER 29, 2024
Ultra-processed foods are part of daily life, filling 60% to 70% of the American diet. That umbrella term covers a wide variety of packaged foods, from snacks carrying added sugar, salt, and saturated fat combined with preservatives for shelf life, additives for flavor, colorants for eye appeal, and chemicals like bisphenols in the packages themselves.
Pharmafile
OCTOBER 29, 2024
Chiesi Global Rare Diseases have announced the results from their BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug ELFABRIO at twice the approved dose in patients who have been treated with agalsidase alfa or beta. The current approved dose of pegunigalside alfa-iwxj (ELFABRIO) is 1miligramg (mg) per kilogram (kg) administered every two weeks. […] The post Chiesi announces phase 3 results from enzyme-replacement study appeared first on Pharmafile.
STAT
OCTOBER 29, 2024
More than a year has passed since Dana-Farber Cancer Institute dumped Mass General Brigham for a rival hospital chain , but the state’s biggest health care system is making a push now to say when it comes to cancer care, MGB’s still got it. Beginning in 2028, Dana-Farber will end its long and nationally acclaimed adult oncology partnership with Brigham and Women’s Hospital.
pharmaphorum
OCTOBER 29, 2024
UK government confirms £1.8bn funding boost to NHS to cut waiting lists, including £1.
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
PharmaVoice
OCTOBER 29, 2024
Pharma pros driving drug development and access for patients with high unmet needs.
BioPharma Dive
OCTOBER 29, 2024
Daniel Quirk, an immunology and neuroscience executive at Bristol Myers Squibb, will be Biogen’s next chief medical officer, while Robin Kramer will replace retiring CFO Michael McDonnell.
pharmaphorum
OCTOBER 29, 2024
An evaluation of digital health technologies for hypertension by the Peterson Health Technology Institute (PHTI) finds some provide a clinical benefit, while others are lacking.On the plus side, the health technology assessment (HTA) body has concluded that tools to help people manage their antihypertensive drug treatment can deliver benefits in reduced blood pressure.
PharmaTech
OCTOBER 29, 2024
WHO and its partners are providing support to countries dealing with mpox outbreaks.
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
pharmaphorum
OCTOBER 29, 2024
Pfizer CEO Albert Bourla hit back at activist investor Starboard Value, saying measures to reset the pharma group are already well in hand
Pharmaceutical Technology
OCTOBER 29, 2024
The EC has approved AstraZeneca's Fasenra as an add-on therapy for adults with relapsing or refractory EGPA.
pharmaphorum
OCTOBER 29, 2024
AbbVie agrees a $1.4bn cash deal to acquire Aliada Therapeutics, adding another anti-amyloid antibody to its Alzheimer's pipeline.
European Pharmaceutical Review
OCTOBER 29, 2024
AbbVie has signed to acquire the biotech Aliada Therapeutics for $1.4 billion. The deal enables the advancement of a potentially best-in-class disease-modifying therapy for Alzheimer’s. Dr Roopal Thakkar , Executive Vice President, Research and Development and Chief Scientific Officer, AbbVie, highlighted that neuroscience is one of AbbVie’s key growth areas.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
OCTOBER 29, 2024
Patients in England and Wales with multiple myeloma are celebrating a decision by NICE to relax strict restrictions on eligibility to receive Pfizer's Elrexfio.In June, the cost-effectiveness agency cleared the use of the BCMAxCD3 bispecific antibody with 'optimised guidance' that allowed it to be used for a narrower range of patients than was covered by the approved label for the drug.
Outsourcing Pharma
OCTOBER 29, 2024
Anu Codaty, VP of global marketing and strategy at Aldevron, is blazing trails in biotech, inspired by a family legacy in medicine and driven to create life-changing therapies.
World Pharma News
OCTOBER 29, 2024
Pharmaceutical scientists from the National University of Singapore (NUS) have identified and characterised a unique multidomain enzyme capable of catalysing two distinct types of reactions, both vital for making drug molecules. Natural products produced by living organisms such as plants, animals, and microorganisms, govern various survival and defence purposes.
Expert insights. Personalized for you.
300 
Let's personalize your content